Concepedia

Aila Holopainen

AH

Statistics

Publications

3

Citations

102

H-Index

3

Active since

2005

Affiliations

Orion Corporation (Finland)(Current)

University of Turku

Turku University Hospital

Turku PET Centre

Aila Holopainen is an author at Orion Corporation (Finland) specializing in neuroscience, nuclear medicine, and neuropharmacology.

Top concepts

Publications per year

2005–2014

3

Publications

3

Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo<sup>®</sup> (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess<sup>®</sup>/Comtan<sup>®</sup> (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment

David J. Brooks, Yves Agid, Karla Eggert et al. · European Neurology · 2005 · 65 citations

Test–retest reliability of 11C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain

Jussi Lehto, Jere Virta, Vesa Oikonen et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 19 citations

, , +7

11C-ORM-13070, a novel PET ligand for brain α2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men

Pauliina Luoto, Sami Suilamo, Vesa Oikonen et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 18 citations

, , +11

1–3 of 3